	ORM PTO-14. S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET: 2002082-0002	IN RE APPLICATION NO.: 10/083,913			
(KE v. 0-03)			APPLICANT: Stoll, Andrew				
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			FILING DATE: February 27, 2002	GROUP:	1614		
TI C DATENIT	DOCUMENTS						
		Amulianut	Issue Date	Class	Subclass		
Examiner's Initials	U.S. Patent No.	Applicant	issue Date	Class	Subclass		
2	4,701,468	Mendy, et al.	October 20, 1987	514	547		
	5,252,333	Horrobin	October 12, 1993	424	422		
đ	5,434,183	Larsson-Backström	July 18, 1995	514	549		
U.S. PATENI	APPLICATIONS	1+0					
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:		
FOREIGN PA	ATENT DOCUMEN	TS					
Examiner's Initials	Document No. Co	Country	Date	Translatio	Translation		
		,		Yes	No		
of	WO 94/28913	PCT	22 December 1994				
	WO 97/39759	PCT	30 October 1997	DE			
	0 289 204 A2	Europe	02 November 1988		EIVE		
9	0 289 204 A3	Europe	02 November 1988	NOV	2 5 2003		
OTHER DOCUMENTS TECH CENTER					TER 1600/29		
Examiner's Initials	Citation (Including	ng Author, Title, Date, Pe	rtinent Pages, Etc.)				
00	Invitation to Pay Additional Fee with a Communication Relating to the Results of the Partial International Search for PCT/US03/05926						
	Adams, J., "Literature Review of Essential Fatty Acids", puterakembara.org, retrieved on July 23, 2003. Cohen, et al., "Lecithin in Mania: A Preliminary Report", Am J Psychiatry 137, 242-243,						
		Cohen, et al., "Lecithin in the Treatment of Mania: Double-Blind Placebo-Controlled Trials", Am J Psychiatry 139, 1162-1164, 1982.					
	Dimmitt, S.B., "Recent Insights into Dietary Fats and Cardiovascular Disease", <i>Clin. Exp. Pharmacol. Physiol.</i> 22, 204-8, 1995 (abstract only)						
1	Locke, et al., "On	nega-3 Fatty Acids in Ma	jor Depression", World Re	view of Nutriti	on and		
	Dietetics, 89: 173-185, 2001.						

	mm 4 7 2003 m					
FORM PTO-14. (REV. 8-83)	S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002082-0002	IN RE APPLICATION NO.: 10/083,913			
(1427.003)		APPLICANT: Stoll, Andrew				
INFORMATIO	N DISCLOSURE STATEMENT	FILING DATE: GROUP: 1614				
(Use seve	eral sheets if necessary)	February 27, 2002				
09	Maidment, I., "Are Fish Oils an Effective Therapy in Mental Illness - an Analysis of the Data", Acta Psychiatr Scand., 102: 3-11, 2000.					
	Mischoulon, et al., "Docosahexanoic Acid and ω-3 Fatty Acids in Depression", <i>The Psychiatric Clinics of North America</i> , 23(4): 785-794, 2000.					
	Puri, et., "The Effects of Olive Oil on ω3 Fatty Acids and Mood Disorders", Arch Gen Psychiatry 57, 2000.					
	Puri, et al., "Eicosapentaenoic Acid in Treatment-Resistant Depression", Archives of General Psychiatry, 59(1): 91-92, 2002.					
	Schreier, H., "Mania Responsive to Lecithin in a 13-Year-Old Girl", Am J Psychiatri 139, 108-110, 1982.					
	Sperling, R., "Dietary Omega-3 Fatty Acids: Effects on Lipid Mediators of Inflammation and Rheumatoid Arthritis", Rheumatic Disease Clinics of North America 17, 373-389, 1991.					
	Sperling, et al., "Dietary ω-3 Polyunsaturated Fatty Acids Inhibit Phosphoinositide Formation and Chemotaxis in Neutrophils", J. Clin. Invest 91, 651-660, 1993.					
	Stoll, et al., "Choline Ingestion Increases the Resonance of Choline-Containing Compounds in Human Brain: An In Vivo Proton Magnetic Resonance Study", Society of Biological Psychiatry 37, 170-174, 1995.					
	Stoll, et al., "Omega 3 Fatty Acids in Bipolar Disorder", Arch Gen. Psychiatry, 56: 407-412, 1999.					
	Stoll, et al., "Omega-3 Fatty Acids and Bipolar Disorder: A Review", <i>Prostaglandins</i> , Leukotrienes and Essential Fatty Acids, 60: 329-337, 1999.					
Stoll, et al., "Methodological Considerations in Clinical Studies of ω3 Fatty Acids in Major Depression and Bipolar Disorder", World Review of Nutrition and Dietetics, 88: 58-67, 2001.						
EXAMINER	Ceri	DATE CONSIDER	ED -101			

RECEIVED

TECH CENTER 1600/2900

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to

applicant.